AN2 Therapeutics (ANTX) and the non-profit medical research organization Drugs for Neglected Diseases initiative announced a collaboration to advance clinical development of AN2-502998, AN2’s oral drug candidate in development for the treatment of chronic Chagas disease.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANTX: